⭐ Recognized by FeedSpot: #12 Best Anesthesiology Blog Worldwide

Uncategorized Published - 1 June, 2018    By - Dr Clemens
nfluence of Depth of Hypnosis on Pupillary Reactivity to a Standardized Tetanic Stimulus in Patients Under Propofol-Remifentanil Target–Controlled Infusion: A Crossover Randomized Pilot Study

AUTHORS: Sabourdin, Nada, MD et al Anesthesia & Analgesia: January 2018 – Volume 126 – Issue 1 – p 70–77 BACKGROUND: Pupillometry allows the measurement of pupillary diameter variations in response to nociceptive stimuli. This technique has been used to monitor the balance between analgesia and nociception. Under general anesthesia, the amplitude of pupillary dilation is related […]

Read More
Uncategorized Published - 1 June, 2018    By - Dr Clemens
Type 2 Perioperative Myocardial Infarction: Can We Close Pandora’s Box?

Author: Martin J. London, M.D., F.A.S.E. Anesthesiology 6 2018, Vol.128, 1055-1059. “…what constitutes [perioperative] myocardial infarction, its subtypes, and treatment strategies[?]” In this issue of the Anesthesiology, Helwani et al.1  address the etiology, classification, and prognosis of perioperative myocardial infarction (MI), a subject of investigation for more than 75 yr now. A unique feature of their study is […]

Read More
Uncategorized Published - 1 June, 2018    By - Dr Clemens
Association of Polypharmacy with Survival, Complications, and Healthcare Resource Use after Elective Noncardiac Surgery: A Population-based Cohort Study

Authors: Daniel I. McIsaac, M.D., M.P.H., F.R.C.P.C. et al  Anesthesiology 6 2018, Vol.128, 1140-1150. Background: Polypharmacy is increasingly prevalent in older patients and is associated with adverse events among medical patients. The impact of polypharmacy on outcomes after elective surgery is poorly described. The authors’ objective was to measure the association of polypharmacy with survival, complications, and […]

Read More
Uncategorized Published - 1 June, 2018    By - Dr Clemens
FDA Approves First Non-Opioid Drug to Treat Opioid Withdrawal

The FDA has approved Lucemyra (lofexidine hydrochloride), a non-opioid, to help lessen the symptoms of opioid withdrawal in adults. Oral lofexidine, a selective alpha 2-adrenergic receptor agonist that inhibits the release of norepinephrine, is approved for up to 14 days of treatment. The FDA notes that it doesn’t treat opioid use disorder, but it can […]

Read More
Uncategorized Published - 31 May, 2018    By - Dr Clemens
Liposomal Bupivacaine Does Not Reduce Inpatient Opioid Prescription or Related Complications after Knee Arthroplasty: A Database Analysis

AUTHORS: Lukas Pichler, M.D. et al  Anesthesiology published on May 21, 2018. Background: Although some trials suggest benefits of liposomal bupivacaine, data on real-world use and effectiveness is lacking. This study analyzed the impact of liposomal bupivacaine use (regardless of administration route) on inpatient opioid prescription, resource utilization, and opioid-related complications among patients undergoing total knee arthroplasties […]

Read More